Literature DB >> 15793677

[Lupus in Germany: analysis within the German lupus self-help organization (LULA)].

R Fischer-Betz1, E Wessel, J Richter, B Winkler-Rohlfing, R Willers, M Schneider.   

Abstract

During the last few decades, the prognosis for patients with systemic lupus erythematosus (LE) has changed from high early mortality to a more chronic longterm course. Although the prevalence of LE has been estimated at 20-50/100,000, data concerning the situation of LE patients in Germany are sparse. Since 2001, a documentation within the German Lupus Self-Help Organisation scheduled for a period of 10 years (LULA) has been recording at the patient level the actual status and the long-term course of a large group of LE patients. A questionnaire adapted from the German rheumatological database is updated once a year and sent to all members.In 2001, 1033 members participated in the documentation. Of these, 92.2% were women (mean age 45.8 years) with a mean disease duration of 9.9 years. 37.6% were employed, and 24.5% were on early retirement. 50.2% rated their overall health status as "not so good" or "poor". Most were receiving treatment with [hydroxy-]chloroquine (35.2%) or azathioprine (21.9%), while 67.9% were receiving corticosteroids. The most frequent comorbidities reported were hypertension (33%), scarring skin disease (24.4%), osteoarthritis (25.2%), osteoporosis (24%), psychiatric disorders/depression (22.9%) and chronic renal disease (22%). Thromboembolic events were reported in 18.5%, myocardial infarction in 2.3% and stroke in 4.8% of cases. Concerning their main contact person for health care, 63.6% specified the rheumatologist. In comparison with other cohort studies and in particular with the German rheumatological database, the data provided exclusively by patients are feasible. Concerning the severity of their disease, their treatment and their global assessment of health status, LULA participants are comparable with other LE patients and can be seen as representative of LE patients in Germany. Further assessment especially of long-term data are needed to obtain additional insights into the burden of the disease and the need for special medical care.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793677     DOI: 10.1007/s00393-005-0644-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  26 in total

1.  Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay
Journal:  J Rheumatol       Date:  1992-11       Impact factor: 4.666

2.  Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features.

Authors:  P López; L Mozo; C Gutiérrez; A Suárez
Journal:  Lupus       Date:  2003       Impact factor: 2.911

3.  Blood pressure is insufficiently controlled in European patients with established coronary heart disease.

Authors:  Eric Boersma; Ulrich Keil; Dirk De Bacquer; Guy De Backer; Kalevi Pyörälä; Don Poldermans; Cristiana Leprotti; Lorenza Pilotto; Esther de Swart; Jaap W Deckers; Jan Heidrich; Susana Sans; Kornelia Kotseva; David Wood; Giovanni B Ambrosio
Journal:  J Hypertens       Date:  2003-10       Impact factor: 4.844

4.  Accrual of organ damage over time in patients with systemic lupus erythematosus.

Authors:  Dafna D Gladman; Murray B Urowitz; Proton Rahman; Dominique Ibañez; Lai-Shan Tam
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

5.  The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus.

Authors:  G D Middleton; J E McFarlin; P E Lipsky
Journal:  Arthritis Rheum       Date:  1994-08

6.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.

Authors:  R Cervera; M A Khamashta; J Font; G D Sebastiani; A Gil; P Lavilla; I Doménech; A O Aydintug; A Jedryka-Góral; E de Ramón
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

8.  Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes.

Authors:  M M Ward; E Pyun; S Studenski
Journal:  Arthritis Rheum       Date:  1995-02

9.  Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death.

Authors:  M Abu-Shakra; M B Urowitz; D D Gladman; J Gough
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

Review 10.  [Epidemiology of rheumatologic health care in Germany].

Authors:  A Zink
Journal:  Z Rheumatol       Date:  1995 Jul-Aug       Impact factor: 1.372

View more
  10 in total

Review 1.  [Burden of illness. First routine report on socio-medical consequences of inflammatory rheumatic disease in Germany].

Authors:  W Mau; W Beyer; I Ehlebracht-König; M Engel; E Genth; B Greitemann; W H Jäckel; A Zink
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

2.  [Possibilities and limits of patient-reported outcome exemplified by systemic lupus erythematosus and the LuLa study].

Authors:  G Chehab; J Richter; M Schneider
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

3.  [Early lupus erythematosus].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

4.  [Fertility preservation for young patients with autoimmune diseases and the need for cytotoxic treatment. Clinical experiences from interdisciplinary consultation].

Authors:  M Henes; J C Henes; M Schmalzing; E Neunhoeffer; R Rothmund; I Kötter; B Lawrenz
Journal:  Z Rheumatol       Date:  2011-02       Impact factor: 1.372

Review 5.  [Antimalarials. A treatment option for every lupus patient!?].

Authors:  R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2009-09       Impact factor: 1.372

Review 6.  Living with systemic lupus erythematosus in the developing world.

Authors:  A Phuti; M Schneider; M Tikly; B Hodkinson
Journal:  Rheumatol Int       Date:  2018-03-26       Impact factor: 2.631

7.  Factors associated with pain coping and catastrophising in patients with systemic lupus erythematosus: a cross-sectional study of the LuLa-cohort.

Authors:  Julia Fischin; Gamal Chehab; Jutta G Richter; Rebecca Fischer-Betz; Borgi Winkler-Rohlfing; Reinhart Willers; Matthias Schneider
Journal:  Lupus Sci Med       Date:  2015-11-12

8.  Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort).

Authors:  A Kernder; J G Richter; R Fischer-Betz; B Winkler-Rohlfing; R Brinks; M Schneider; G Chehab
Journal:  Lupus       Date:  2020-02       Impact factor: 2.911

9.  Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort.

Authors:  Anna Kernder; Jutta G Richter; Rebecca Fischer-Betz; Borgi Winkler-Rohlfing; Ralph Brinks; Martin Aringer; Matthias Schneider; Gamal Chehab
Journal:  Lupus       Date:  2021-01-05       Impact factor: 2.911

10.  Off-label use of rituximab for systemic lupus erythematosus in Europe.

Authors:  Monica Rydén-Aulin; Dimitrios Boumpas; Irene Bultink; Jose Luis Callejas Rubio; Luis Caminal-Montero; Antoni Castro; Agustín Colodro Ruiz; Andrea Doria; Thomas Dörner; Cristina Gonzalez-Echavarri; Elisa Gremese; Frederic A Houssiau; Tom Huizinga; Murat Inanç; David Isenberg; Annamaria Iuliano; Søren Jacobsen; Juan Jimenéz-Alonso; Lászlo Kovács; Xavier Mariette; Marta Mosca; Ola Nived; Joaquim Oristrell; Manuel Ramos-Casals; Javier Rascón; Guillermo Ruiz-Irastorza; Luis Sáez-Comet; Gonzalo Salvador Cervelló; Gian Domenico Sebastiani; Danilo Squatrito; Gabriella Szücs; Alexandre Voskuyl; Ronald van Vollenhoven
Journal:  Lupus Sci Med       Date:  2016-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.